Natural killer (NK) cells have an important function in the antitumor response early after stem cell transplantation (SCT). As part of a prospective randomized phase III study, directly comparing the use of CD3 þ /CD19 þ -depleted peripheral blood stem cell (PBSC) harvests with CD34
Introduction
Natural killer (NK) cells are potent immune effector cells involved in the clearance of virus-infected and tumor cells. They are able to lyse infected or abnormal cells without prior sensitization or preactivation by antigen-presenting cells. NK cells survey potential target cells through a range of inhibitory and stimulatory receptors that detect the loss (or reduction) of expression of human leukocyte antigen (HLA) class I molecules or other nonclassical HLA class I-specific signals. 1, 2 The balance between the inhibitory and stimulatory signals triggers and modulates the NK cell effector function and the response of NK cells toward other cells.
The cytolytic function of NK cells is regulated by killer cell immunoglobulin-like receptors (KIR) including both inhibitory receptors (KIR-DL) and stimulatory receptors (KIR-DS). Whereas the ligands for the activating receptors is not yet unequivocally established, the ligands of KIR-DL receptors are specific for HLA class I molecules. KIR receptors are clonally distributed among NK cells within each individual. 3 Next to the KIR, another important receptor in modulating NK cell responses is the CD94:NKG2 heterodimeric complex. This receptor is part of the C-type lectin family and its ligand is the HLA-E class I molecule. 4 The CD94:NKG2 heterodimer can either have an inhibitory (NKG2A) or a stimulatory (NKG2C) function. Other NK cell receptors include the natural cytotoxicity receptors (NKp30, NKp44, and NKp46) and NKG2D (a C-type lectin homodimer). These receptors are capable of activating NK cells, whereby inducing NK cell-mediated cytolytic responses. 5 As NK cells are efficient effectors in eradicating tumor cells, they have an important function in the anti-tumor response after allogeneic stem cell transplantation (SCT). [6] [7] [8] [9] In HLA-haploidentical SCT, Ruggeri et al. 10 showed that donor alloreactive NK cells isolated from peripheral blood of the recipient were able to lyse tumor cells derived from the recipient, implying that within 1 month after SCT, NK cells may be able to provide some degree of immune reactivity by targeting residual tumor cells still present in the recipient. Indeed, fast recovery of NK cells and predicted alloreactivity toward host tumor cells has been associated with decreased relapse rates and better overall survival of the patient. [11] [12] [13] Recently, however, Nguyen et al. 14 showed that early reconstituting NK cells have an immature phenotype and that NK cell alloreactivity is impaired at an early stage after haploidentical SCT. The results of this study emphasize that proper reconstitution of the NK cell receptor repertoire is probably more important for the induction of alloreactive NK cell responses than just fast NK cell recovery. One way to overcome delayed immune reconstitution of NK cells after SCT is to change the selection procedure of the graft. Recent data have shown that graft selection for haploidentical SCT by depletion of CD3 þ and CD19 þ cells, instead of positive CD34 þ cell selection, leads to faster engraftment and better overall immune reconstitution. 15 In our centre, a phase III clinical study started in January 2006, directly comparing the use of CD3 þ /CD19 þ -depleted peripheral blood stem cell (PBSC) harvests with commonly applied CD34
þ -selected PBSC harvests in allogeneic HLAmatched SCT. We investigated the immunological recovery and function of the NK cells after allogeneic SCT for a follow-up period of 1 year and compared the results between patients either having received a CD3 þ /CD19 þ -depleted graft or a CD34 þ -selected graft.
Materials and methods

Study population
In a single centre randomized phase III clinical study at the Radboud University Nijmegen Medical Centre, patients with AML in first complete remission, ALL in first complete remission or high risk MDS (RAEB, RAEB-t) in complete remission, eligible for allogeneic peripheral blood stem cell transplantation (PSCT) received G-CSF-mobilized PBSCs of an HLA-identical sibling donor (SIB) or an HLA-A, -B, -C, -DR, -DQ-matched voluntary unrelated donor. In this study, patients were randomized to receive a PBSC graft processed either by positive CD34 þ immunomagnetic selection or T (CD3 þ ) and B-cell (CD19 þ ) depletion by negative immunomagnetic selection using a CliniMACS cell selector device (Miltenyi Biotec, Bergisch Gladbach, Germany). All transplants contained at least 3 Â 10 6
CD34
þ cells and 0.5 Â 10 6 T cells/kg body weight. The amount of T cells was achieved by adding back cells from the harvest. Between January 2006 and November 2007, 23 patients were included in this study. This study was approved by the medical ethics committee of the Radboud University Nijmegen Medical Centre and written informed consent was provided by patients and donors according to the Declaration of Helsinki. Table 1 outlines the demographics of the patients selected for this study. This study is registered at http://clinicaltrials.gov as T-cell and Bcell depletion in allogeneic PSCT (registration number: NCT00306332).
Patient treatment procedures
All patients transplanted with a graft from a sibling donor were conditioned with idarubicine (total dose 42 mg/m 2 ) i.v., 16 cyclophosphamide (120 mg/kg body weight) i.v., and fractionated total body irradiation (TBI) given in two equal fractions on days À2 and À1 to a total dose of 9 Gy. In two patients, TBI was replaced by busulphan (3.2 mg/kg body weight) intravenously. In patients transplanted with a graft from a voluntary unrelated donor, the conditioning regimen consisted of cyclophosphamide (120 mg/kg body weight), anti-thymocyte globulin (2 mg/kg body weight) every 24 h at four consecutive days (day À7 to À3) i.v. and fractionated TBI given in two equal fractions on days À2 and À1 to a total dose of 9 Gy. The stem cells were infused 24 h after completion of TBI or 72 h after the last dose of busulphan. All patients were treated with cyclosporine A 3 mg/kg/d i.v. from day À1 to þ 14, followed by 2 mg/kg/d i.v. infusion until oral administration of cyclosporine A (6 mg/kg/d) was possible. Cyclosporine A was gradually tapered off and discontinued 12 weeks post-grafting. Patients who did not develop acute graft versus host disease (GVHD) 4grade 2 and/or chronic GVHD, according to the criteria described by Glucksberg and Shulman, received preemptive donor lymphocyte infusion at a dose of 0.1 Â 10 8 CD3 þ cells/kg body weight. All patients received oral selective gut decontamination (ciprofloxacin), as well as co-trimoxazole for pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis of herpes infections.
Collection and preparation of samples
Blood samples (50 ml) were taken from patients before and at 0.5, 1, 2, 3, 6, 9, and 12 months after SCT. When possible, blood samples were collected from each donor before SCT. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using Lymphoprep (Nycomed Pharma, Roskilde, Denmark). A fraction of the isolated PBMC was used to analyze the phenotype of the NK cells in detail. The remaining cells were cryopreserved in liquid nitrogen until further use. To evaluate immunological recovery, immunophenotyping was performed on fresh blood samples from patients.
Phenotypic analysis
The phenotype of NK cells was analyzed by four-color flow cytometry measured on a Coulter Epics XL (Beckman Coulter, Miami, FL, USA). For cell surface staining, the after conjugated mAbs were used: CD45-PE, CD16-FITC (Dako, Glostrup, Denmark), CD3-ECD, CD56-PCy5, CD158a,h-PE, CD158b 1 b 2 ,j-PE, NKG2A-PE, NKp30-PE, NKp44-PE, NK46-PE (Beckman Coulter), NKB1-PE (BD Biosciences, Erembodegem, Belgium), CD94-PE (Immunotech, Marseille, France), NKG2C-PE, and NKG2D-PE (R&D Systems, Minneapolis, CA, USA). Isotype controls were used for marker settings. Analysis was performed using CXP analysis software (Beckman Coulter). All flow cytometric analyses were performed with a combination of CD3, CD16, and CD56 mAbs combined to a fourth specificity to gate specifically on CD3 
Functional analysis
For functional studies, cryopreserved PBMC were thawed and cultured overnight in the presence or absence of rhIL-2 (100 U/ml; Chiron, Amsterdam, the Netherlands) and rhIL-15 (10 ng/ml; BioSource International, Camarillo, CA, USA) in culture medium consisting of RPMI 1640 supplemented with pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 mg/ml), and 10% human pooled serum, in a 37 1C 95% humidity, 5% CO 2 incubator.
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Chromium-release assay. Pre-stimulated or unstimulated PBMC were used to examine the NK cell cytolytic activity using the major histocompatibility complex class I-deficient human erythroleukemia K562 cell line (ATCC; CCL-243) as target cells at PBMC:target ratios ranging from 80:1 to 0.625:1 in a standard 4-h 51 Cr-release assay. All experiments were performed in triplicates and for each patient all samples were run together in one assay to avoid inter-assay variation. The percentage specific lysis was calculated as follows: % specific lysis ¼ ((experimental release-spontaneous release)/(maximum release-spontaneous release)) Â 100%. To express NK cell cytolytic activity independent of an arbitrary selection of E:T ratio and to allow reliable comparisons between samples of patients tested at different moments in time, the specific lysis was converted into lytic units (LU). LU are defined as the number of effector cells contained in 10 6 effector cells required to lyse 20% of the target cells. 17 Redirection assays. Redirection assays were performed using the P815 cell line (ATCC; TIB-64) as target cells. P815 cells were incubated in culture medium with pre-stimulated PBMC at an E:T ratio of 1:2 in the presence of mAbs (10 mg/ml) specific for NKG2C, NKG2A, and NKp46 (R&D Systems) or with IgG1, IgG2a, and IgG2b isotype controls (R&D Systems) at 37 1C 95% humidity and 5% CO 2 . E:T ratios were based on the amount of live NK cells present in the PBMC fractions after overnight culture. To measure NK cell degranulation, cells were washed after 2 h of incubation, stained on ice with fluorochrome-conjugated anti-CD107a (BD Biosciences), anti-CD56, and anti-CD3 mAbs and analyzed by flow cytometry. To calculate the specific degranulation, nonspecific degranulation induced by isotype controls was deducted from the degranulation given by specific triggering. IFN-g produced by NK cells was analyzed by intracellular staining after 5 h of incubation with P815 target cells at 37 1C with 5 ng/ml of Brefeldin A (Sigma-Aldrich, Zwijndrecht, The Netherlands) for the last 4 h. First, a surface staining was performed using anti-CD56 and anti-CD3 mAbs. For intracellular staining, Fix and Fix/Perm buffer (eBioscience, San Diego, CA, USA) were used according to the manufacturer's instructions in combination with IFN-gPeCy7 mAb (eBioscience).
Statistical analysis
Nonparametric tests were used to compare continuous variables between two groups. To test the differences between both patient groups or within one group between donors and recipients after SCT, a Mann-Whitney U-test was performed. A Wilcoxon-signed rank test was used to compare the differences within each group between recipients before and after SCT. Po0.05 was considered significant.
Results
Patients
Patients eligible for inclusion in the study were randomized on a 1:1 basis for treatment with either a positive CD34 þ -selected graft (CD34 group) or a T-and B-cell-depleted graft (CD3 þ / CD19 þ depletion; CD3/19 group). Between January 2006 and November 2007, 14 patients were included in the CD34 group and 9 patients were included in the CD3/19 group. Patient and donor characteristics are depicted in Table 1 . The composition of the grafts selected by CD34 Table 2 . After SCT, patients of both groups showed similar engraftment kinetics and there were no remarkable differences in the immunosuppressive regimens between the two groups (Table 3 ). There were no major differences in the occurrence of GVHD, fungal infections, and relapse rate. The incidence of bacterial infections was slightly higher in the CD34 group, possibly because of the fact that the CD34 þ -selected grafts contained less monocytes and granulocytes. In case of viral infections, we saw a tendency toward a higher infection rate in the CD3/19 group. This is due to a higher number of cytomegalovirus (CMV) reactivations that occurred within the CD3/19 group (4 patients versus 1 patient in the CD34 group).
Repopulation of NK cells after SCT
To study NK cell repopulation and reconstitution of the NK cell receptor repertoire, peripheral blood samples were taken from each patient before SCT and at 0.5, 1, 2, 3, 6, and 12 months after SCT and were analyzed for the presence of NK cells by flow cytometric analysis. At each time point, the absolute numbers of NK cells were analyzed within whole blood samples (Figure 1a ). In the CD34 group, at day 14 after SCT, only limited amounts of NK cells were present in the peripheral blood as compared with absolute NK cell numbers before SCT. The absolute numbers of NK cells reached pre-SCT levels 1 month after SCT. Thereafter, levels slowly increased and reached significant levels at 6 months after SCT (Po0.05, compared with numbers before SCT). In the CD3/19 group, absolute numbers of NK cells in the peripheral blood reached pre-SCT level already at 14 days after SCT. One month after SCT, the absolute NK cell numbers increased even further (Po0.05). Comparison of the CD34 group with the CD3/19 group shows that at day 14 after SCT significantly higher numbers of NK cells were present in the CD3/19 group (Po0.05).
The repopulation of the CD56 bright and CD56 dim NK cell subsets was analyzed within isolated PBMC fractions by gating on the lymphocytes by CD45 þ and a low side scatter and subsequently on CD56 þ and CD3 À cells. In the CD34 group, the repopulation of the two NK cell subsets seemed to start with the development of the CD56 bright NK cells. The balance between the CD56 bright and CD56 dim NK cell subsets was in favor of the CD56 bright NK cells until 6 months after SCT (Figure 1b) . This is comparable with the results described by earlier studies in which the development of NK cells after SCT was studied. 18, 19 In contrast, in the CD3/19 group, both NK cell subsets were already present at 14 days after SCT (data not shown). Moreover, the outgrowth of the CD56 bright NK cell subset was less profound as seen within the CD34 group and the balance between the CD56 bright and CD56 dim NK cell subsets was more comparable with the donor situation before SCT. In contrast to the different reconstitution kinetics of the NK cells, the reconstitution of both T and B cells was comparable between the CD34 and CD3/19 group during the first 3 months after SCT (Supplementary Figure S1) .
Reconstitution of the NK cell receptor repertoire
As the repopulation of the CD56 dim and CD56 bright NK cell subsets was much faster in the CD3/19 group, suggesting an earlier presence of mature NK cells, we investigated whether this phenomenon was also reflected in the reconstitution of the NK cell receptor repertoire after SCT.
Comparison of KIR expression between the CD34 and the CD3/19 groups
In both groups, reconstitution of KIR2DL/S1, KIR2DL/S2/3, and KIR3DL1 expression was monitored in the total NK cell population (CD45 þ CD3 À CD56 þ ) during the follow-up at different time points after SCT.
Within the CD34 group, the percentages of KIR2DL/S1 þ NK cells never reached donor levels throughout the entire followup. At 1 year after follow-up, on average only 10% of the NK cells expressed KIR2DL/S1 compared with 30% of the NK cells in the donor. Moreover, the percentage of KIR2DL/S2/3-expressing NK cells was strongly reduced at 3 and 6 months, but did reach donor levels at 1 year post-SCT (Figure 2 ). The reconstitution of KIR3DL1 þ NK cells already reached donor level within 1 month after SCT. Notably, during the remaining follow-up, the percentage of KIR3DL1 þ NK cells was decreased and did not regain donor levels during the rest of the follow-up. Compared with KIR2DL/S, the reconstitution of KIR3DL1 seemed to show an opposite reconstitution pattern over time. This phenomenon has earlier been described after HLAmismatched/haploidentical SCT. 20 In the CD3/19 group, KIR reconstitution was faster compared with the CD34 group. Although in the CD34 group full reconstitution took a year, as has also been described by others, 21 the NK cells in the CD3/19 group reached normal expression frequencies directly after SCT. Here, the amount of KIR2DL/S1
þ NK cells was only significantly decreased up to 1 month after SCT compared with donor level and within 1 year after SCT, expression levels were fully restored. In addition, the amount of KIR2DL/S2/3 þ and KIR3DL1 þ NK cells were already The immunosuppression for each group is given in median days after transplantation with ranges (CsA) and the number of patients receiving additional steroids. c Within 3 months after stem cell transplantation, two patients died within the CD34 group and one patient died within the CD3/19 group. 
after SCT within the CD34 group and the CD3/ 19 group. NK cell numbers were analyzed within whole blood samples of recipients before SCT (R) and at several time points after SCT using flow cytometry. Within each group, differences between recipients before SCT and after SCT were analyzed using the Wilcoxon-signed rank test. The Mann-Whitney U-test was used to test differences between both groups; *Po0.05, ***Po0.001. dim NK cell subsets before SCT and at different time points after SCT. R, recipients before SCT; D, donors. Within each group, differences between donors and recipients after SCT were analyzed using the Mann-Whitney U-test; **Po0.01, ***Po0.001.
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at donor level at 14 days after SCT (data not shown). Remarkably, during the remaining time of the follow-up, the number of KIR2DL/S2/3 þ NK cells was enhanced from a median level of 19% at 2 months after SCT to 30% at 1 year after SCT. Similar to the CD34 group, reconstitution of the KIR3DL1 þ NK cells followed the same pattern over time and did not significantly decrease compared with donor level. Thus, as the reconstitution of the number of KIR2DL/S þ NK cells was rather slow in the CD34 group and was significantly lower within the first months after SCT, frequencies of KIR2DL/S expression in the CD3/19 group were not significantly different from donor level and reconstituted faster to full donor level. In summary, the NK cells quickly recovered in the CD3/CD19 group and maintained similar percentages of KIR-bearing NK cells as compared with the donor before SCT.
Alternative reconstitution of CD94:NKG2A/C expression
During NK cell development, KIR expression is preceded by expression of CD94:NKG2A. 22 In the first months after SCT, NK cell subsets were shown to be characterized by a high frequency of CD94:NKG2A expression and low expression of KIR. [19] [20] [21] This suggests that at early stages after SCT, the function of NK cells is primarily regulated through the interaction of CD94:NKG2 heterodimeric complexes with HLA-E molecules. In both groups, the frequency of CD94-expressing NK cells was upregulated during the first 3 months after SCT, after which the percentage of CD94-expressing NK cells slowly decreased toward donor level (Figure 3 ). In the CD34 group, the amount of CD94 þ NK cells was higher during the first months after SCT. However, frequencies of CD94-expressing NK cells between the two groups were similar from 3 months to 1 year after SCT. Remarkably, the NKG2A expression levels in the CD3/19 group were significantly decreased from a median percentage of 76% at 1 month to 36% at 1 year after SCT (Po0.05) whereas at the same time, the frequency of NKG2C-expressing NK cells was significantly increased from a median of 8-53%, respectively (Po0.01) (Figure 4a ). This phenomenon seemed to be specific for the CD3/19 group, as this was not seen within the CD34 group (Figure 4b) .
We observed no differences in the reconstitution of the other activating NK cell receptors ( Figure 5 ). Although the frequencies of NKp30 expression seemed to drop slightly in the CD3/19 group as compared with the CD34 group, percentages of NKG2D and natural cytotoxicity receptor expression were similar in both groups after SCT. In addition, frequencies of NKG2D-, NKp30-, and NKp44-expressing NK cells did not significantly change compared with donor levels. In both groups, the amount of NKp46 expression was significantly higher directly after SCT and remained above donor levels throughout the rest of the follow-up.
Cytolytic activity against HLA class I-negative target cells
We observed that, whereas in the CD34 group only few NK cells were present at day 14 after SCT and full repopulation in the CD34 group took place from 1 to 2 months after SCT, in the CD3/19 group the repopulation of NK cells had already taken place just after SCT. Moreover, we observed that the ratio of CD56 bright versus CD56 dim NK cells in the CD3/19 group after SCT was distinct from that found in the CD34 group. Thus, we set out to investigate whether the repopulation profiles and phenotypic differences were paralleled by a distinct functional activity of the cell populations. To assess the cytolytic potential of the repopulated NK cells after SCT, we performed À NK cell population in freshly isolated PBMC fractions of donors (D) and of recipients before (R) and at 1, 3, 6, and 12 months after SCT, was analyzed using flow cytometry. Data are shown for the CD34 group and the CD3/19 group. Within each group, differences between donors and recipients after SCT were analyzed using the Mann-Whitney U-test; **Po0.01, ***Po0.0001. cytolytic assays using the K562 cell line as a target. Before the assay, NK cells were incubated overnight in the absence or presence of IL-2 and IL-15. Unstimulated NK cells derived from the CD34 and CD3/19 group before SCT showed equal cytolytic activity (Figure 6a ). But, after SCT, the NK cells in the CD3/19 group not only seemed to show a faster reconstitution of the different NK cell subsets and the NK cell receptor repertoire, at 14 days after SCT, they also showed stronger cytolytic capacity. Moreover, at this time point, the cytolytic activity was even higher than before SCT (Po0.05) and this was maintained throughout the rest of the follow-up. Parallel to the duration of NK cell repopulation, in the CD34 group, enhanced cytolytic activity levels were only reached at 1 to 2 months after SCT. Although enhanced, the trend in cytolytic activity was similar for the pre-stimulated NK cells (Figure 6b ). This implies that the use of CD3 þ /19 þ -depleted grafts for SCT may lead to an earlier and longer time frame of NK cell cytolytic activity after SCT.
Diminished NK cell inhibition through NKG2A triggering in the CD3/19 group
Earlier studies showed that high expression levels of CD94:NKG2A after SCT may lead to impaired cytolytic NK cell function.
14 As the NKG2A:NKG2C ratio in the CD3/19 group was in favor of the stimulatory NKG2C receptor, we set out to investigate whether this distinct phenotype was associated with enhanced functional activity. To this end, we set up a redirection assay in which NK cells were triggered by P815 cells labeled with NKG2C-and NKp46-specific antibodies in the absence or presence of NKG2A-specific antibodies. Typically, triggering of NK cells with NKp46 and NKG2C antibodies leads to NK cell degranulation, whereas NKG2A triggering leads to inhibition of NK cell degranulation. At 1 month after SCT, the CD3/19 and CD34 groups showed similar NKG2A-mediated inhibition of NK cell degranulation (Figure 7) , which is in line with the similar percentage of NKG2A-expressing NK cells in both groups ( Figure 5 ). Notably, from 1 month post-SCT onward, Figure 5 Reconstitution of activating NK cell receptors NKG2D, NKp30, NKp44, and NKp46. Percentages of NKG2D-, NKp30-, NKp44-, and NKp46-expressing CD45 þ CD56 þ CD3 À NK cells were analyzed in freshly isolated PBMC fractions for both the CD34 group and the CD3/19 group at 1, 3, 6, and 12 months after SCT. Within each group, differences between donors and recipients after SCT were analyzed using the Mann-Whitney U-test; **Po0.01, ***Po0.0001. only in the CD3/19 group, the inhibitory effect of NKG2A triggering was diminished, corresponding with an increased frequency of CD94:NKG2C
þ NK cells and a decreased percentage of CD94:NKG2A þ NK cells. In the CD34 group, the inhibitory effect of NKG2A triggering was maintained. In addition, the percentage of degranulating NK cells as induced by NKG2C and NKp46 triggering tended to be higher in the CD3/19 group as compared with the CD34 group (3 months: median of 16% versus 3%; at 6 months: median of 9% versus 3%). The level of degranulation, induced by NKG2C and NKp46 triggering, was also reflected in the IFN-g production (data not shown), as the NK cells within the CD3/19 group produced higher levels of IFN-g.
In conclusion, we show that the use of CD3 þ /19 þ -depleted grafts for allogeneic HLA-matched SCT leads to a preferential development of NKG2C-expressing NK cells, paralleled by a loss of NKG2A-mediated inhibition of NK cell degranulation at later stages after SCT.
Discussion
Immediately after SCT, alloreactive NK cells have been shown to be beneficial not only for boosting the anti-tumor response, but also for the prevention of GVHD as well as infections. In these cases, full functional activity of NK cells already in the early phase after SCT is essential, and, therefore, the presence of NK cells in the graft seems to be beneficial for transplant outcome. 15, 23 In this study, we show that patients that received a CD3 þ /CD19 þ -depleted graft, which contains NK cells in substantial numbers, exhibited a faster recovery of a functional NK cell receptor repertoire as compared with patients that received a conventional CD34 þ -selected graft, whereas both groups were treated under the same immunosuppressive regimen as part of their GVHD prophylaxis. Furthermore, transplantation with a CD3 þ /CD19 þ -depleted graft resulted in the development of a functionally different NK cell population that was more prone to activation through the NKG2C:CD94 receptor complex and less sensitive to inhibition through the NKG2A:CD94 receptor complex.
Several studies have shown that the beneficial effect of NK cell activity after SCT is dependent on the fast reconstitution of a cytolytic NK cell repertoire that is regulated by KIR 24 and that a slower reconstitution toward a KIR-dependent repertoire is associated with poor clinical outcome. 14, 20, 21, 25 In the group receiving a CD3 þ /CD19 þ -depleted graft, we observed functional NK cells already at 14 days after SCT, with KIR-expressing NK cell numbers similar to those found in the donor before SCT. After 14 days, the cytolytic activity and number of KIRexpressing cells increased even further and remained high during follow-up. In contrast, in patients that received a CD34 þ -selected graft KIR reconstitution took much longer, whereby during the first 6 months after SCT, the repertoire was skewed toward NKG2A-expressing cells rather than KIR-expressing cells, a phenomenon also described by others. 21 So it would seem that the conditions created after SCT using a CD3 þ /CD19 þ -depleted graft support the development of a KIR-based repertoire. The clinical relevance of such a finding is exemplified by the fact that in the clinical studies that reported a function for NK cells in the anti-tumor response after SCT, the nature of the interaction between KIR and HLA class I seemed decisive for the outcome. 8, 9, [25] [26] [27] The most straightforward example hereof is the haploidentical SCT setting, whereby donor NK cells expressing KIR specific for self-HLA class I ligands sense the absence of this ligand in the recipient. This Figure 7 Redirected degranulation of NK cells by specific triggering of the activating NKG2C and NKp46 receptors in the presence or absence of NKG2A specific antibodies. PBMC fractions of the CD34 group (n ¼ 6) and the CD3/19 group (n ¼ 5) were stimulated overnight with IL-2 (100 U/ml) and IL-15 (10 ng/ml) and subsequently incubated for 2 h at an NK:target cell ratio of 1:2 in a redirection assay using P815 target cells and NKG2A, NKG2C, NKp46, or isotype control mAbs. Specific degranulation was determined within the CD56 þ CD3 À NK cell population as the percentage of CD107 þ CD56 þ CD3 À NK cells with specific mAbs minus the percentage of CD107 þ CD56 þ CD3 À NK cells in the presence of isotype control mAbs. Negative values are displayed as equal to 0. Specific degranulation was determined for recipients at 1, 3, and 6 months after SCT. Significance of inhibition through NKG2A was analyzed using the Wilcoxon-signed rank test; NS ¼ not significant, *Po0.05. Cr-labeled K562 target cells in a standard 4-h 51 Cr-release assay. Displayed are the lytic units (LU) within each PBMC fraction of the CD34 group and the CD3/19 group before SCT (R) and at 0.5, 1, 2, 3, 6, and 12 months after SCT. LU comparisons between recipients before SCT and after SCT were analyzed using the Wilcoxon-signed rank test; *Po0.05, **Po0.01. Differences between groups were analyzed using the Mann-Whitney U-test; *Po0.05. results in cytolytic responses against the recipient tumor cells and reduced risk of relapse ('missing self'). 8, [28] [29] [30] A similar phenomenon can also be observed in HLA-matched SCT for AML, when the donor expresses a KIR for which the ligand is missing in the patient ('missing ligand'). 27 Although it is appealing to incorporate the receptor-ligand model into the criteria for donor selection in HLA-matched SCT, recent findings in the haploidentical setting showed that this model is more complex as not only inhibitory KIR, but also certain activating KIR have an important function in the process of tumor cell recognition and eradication. 31 The high NK cell numbers observed in the CD3/19 group may be the result of NK cells present in the graft. Indeed, it has been shown that alloreactive NK cells can expand and persist for at least 28 days. 32 Alternatively and not mutually exclusive, the high numbers may be a result of de novo generation from CD34 þ progenitor cells, as the dose of CD34 þ cells was much higher in the CD3/19 group as compared with the CD34 group.
Freud and Caligiuri 33 have proposed a model for NK cell development based on different maturation stages of NK cells in secondary lymphoid organs. According to this model, NK cells go through four maturation stages before they become mature peripheral NK cells (stage V). In the last stage (IV) before reaching maturity, the NK cells have high expression of CD56 and express NKG2A. In stage V, the NK cells have a lower level of CD56 expression and are KIR and/or NKG2A positive. 34 This fits the observations made after SCT using a CD34 þ -selected graft. We and others 18, 21 observed that most of the NK cells found in peripheral blood in the first 6 months after SCT resemble those in stage IV (CD56 bright and NKG2A þ ), and that gradually over time, more NK cells reach stage V. Clinical data suggest that a sustained high number of NK cells resembling stage IV (CD56 bright and NKG2A þ ) is associated with poor clinical outcome. 14, 20 Interestingly, the formation of the NK cell receptor repertoire in case of CD3 þ /CD19 þ -depleted grafts is clearly different. Not only is there a faster shift to a KIR-based repertoire, but the reduction in NKG2A-expressing cells seems to coincide with the occurrence of a population expressing the activating NKG2C receptor. At 1 year after SCT, as much as 50% of the NK cells express NKG2C. Normally, in peripheral blood only few mature NK cells express NKG2C. Moreover, only low numbers of stage IV NK cells express NKG2C. 33 The occurrence of the NKG2C-expressing NK cell population may have important consequences for the anti-tumor response after SCT. The stimulatory receptor NKG2C, such as NKG2A, binds to HLA-E, although the affinity of NKG2C for HLA-E seems to be lower. 35 The NK cells in the CD3/19 group were more prone to activation by NKG2C and NKp46 triggering in terms of cytolytic activity and IFN-g production. Furthermore, the inhibitory effect of NKG2A triggering on the whole population was lost at later stages after SCT, coinciding with the occurrence of NKG2C-expressing NK cells. In contrast, NK cells in the CD34 group maintained a high frequency of NKG2A-expressing cells and NKG2A triggering completely inhibited cytolytic NK cell activity. A similar observation was made for NK cells after CD34 þ haploidentical SCT.
14 Moreover, in this patient group, practically all NK cells expressed NKG2A during the first 4 months after SCT and expression of HLA-E on the tumor cells completely blocked the cytolytic activity of NKG2A þ NK cells. This may suggest that a shift in balance from a CD94:NKG2A þ to a more CD94:NKG2C þ phenotype in the CD3/19 group, and a subsequent overruling of NKG2A-mediated inhibition, may lead to a stronger anti-tumor response and a better clinical outcome.
Although the two patient groups are yet too small to compare clinical outcomes, we did observe that human CMV reactivation was more common in the CD3/19 group (4 out of 9 patients) than in the CD34 group (1 out of 14 patients). In earlier studies, it was shown that CMV has an impact on the expression of NK cell receptors on NK cells and CD8 þ T cells irreversibly resulting in increased CD94:NKG2C expression levels and subsequently the loss of CD94:NKG2A expression. [36] [37] [38] However, when we excluded the CMV-positive patients from our analyses, the change from a overall NKG2A þ to a more NKG2C þ phenotype was also seen in patients that did not suffer from CMV reactivation (data not shown). The alternative reconstitution of the NK cell receptor repertoire, characterized by the change in balance of CD94:NKG2A þ NK cells to more CD94:NKG2C þ NK cells, and its impact on clinical outcomes after SCT is therefore a subject for further study.
In summary, in this study we show that the use of selectively depleted grafts (CD3 þ /CD19 þ cell depletion) as compared with CD34
þ -selected grafts in HLA-matched SCT leads to faster reconstitution of the KIR repertoire resulting in a longer time frame after SCT for NK cell cytolytic activity. Moreover, at a later stage after SCT, there was a large population of NKG2C-expressing cells and NK cells seemed to be more prone to activation. Extended studies are underway to reveal whether these findings have an effect on clinical outcome.
